Highlights on gemcitabine vs mFOLFIRINOX in resected pancreatic cancer: PRODIGE 24/CCTG PA6
ESMO 2021: PRODIGE 24 Trial
Share.
About Author
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Related Posts
-
DNA-based therapy combined with gemcitabine shows promising survival benefit in platinum-resistant ovarian cancer
-
Overall survival benefit with elenagen plus gemcitabine in platinum-resistant ovarian cancer
-
Consistency is the key: regular moderate exercise linked to lower digestive system cancer risk and mortality